Not recruiting
Non-small cell lung cancer stage IV+2
Not recruitingStudy comparing brigatinib alone versus brigatinib with carboplatin and pemetrexed combination as first treatment for patients with advanced ALK-positive lung cancer
Registered drugNo placebo
Study comparing brigatinib alone versus brigatinib with carboplatin and pemetrexed combination as first treatment for patients with advanced ALK-positive lung cancer
Registered drugNo placebo
- Disease:Non-small cell lung cancer stage IVNon-small cell lung cancer stage IIIB+1
- Substances:BrigatinibCarboplatin+1
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Brigatinib
- Sponsor:Intergroupe Francophone De Cancerologie Thoracique